Innovative Bispecific Nanobody Targeting IL18R1 and IL18RAP for Advanced Colorectal Cancer Therapy

VHH-P312 is a bispecific, humanized nanobody designed to target interleukin 18 receptor 1 (IL18R1) and interleukin 18 receptor accessory protein (IL18RAP). Currently in the Biological Testing stage, this cutting-edge molecule harnesses the precision of nanobody engineering to modulate immune pathways relevant to colorectal cancer. By simultaneously engaging IL18R1 and IL18RAP, VHH-P312 presents a novel immunomodulatory approach with potential to address those patient populations where current therapies remain limited. Its humanized, single-domain antibody format is tailored to deliver comprehensive coverage of these clinically relevant targets, positioning VHH-P312 as a promising candidate in the rapidly evolving oncology landscape.

Licensing Opportunity

VHH-P312 is currently available for out-licensing and strategic collaboration. Partners interested in innovative immunotherapy solutions for colorectal cancer are invited to engage in co-development and commercialization opportunities.

Development Phase

Modality

VHH-P312 is a bispecific antibody composed of two humanized single-domain nanobody components: one targeting the N-terminal extracellular domain of IL18R1 and the other targeting the N-terminal ECD of IL18RAP, connected via a GGGGSG flexible linker and fused to a human Fc fragment. This unique structural architecture offers enhanced tumor penetration, excellent stability, and reduced immunogenicity due to its small size and humanized sequence. The bispecific format enables simultaneous, high-affinity targeting of both IL18R1 and IL18RAP, which is especially advantageous in solid tumors like colorectal cancer, where microenvironment complexity and heterogeneous antigen expression often limit therapeutic efficacy. The Fc fusion further prolongs circulation time and augments effector functions, maximizing clinical potential in colorectal cancer management.

Target

IL18R1 and IL18RAP are integral components of the IL-18 signaling pathway and function as membrane-bound receptor proteins. IL18R1 and IL18RAP are expressed on various immune cells, including T lymphocytes, natural killer cells, and select epithelial tissues. In colorectal cancer, IL18R1 and IL18RAP have been implicated in the regulation of inflammatory responses, immune cell recruitment, and tumor-promoting microenvironment alterations. Targeting IL18R1 and IL18RAP disrupts pro-tumorigenic signaling cascades, offering a rationale for therapeutic intervention. VHH-P312, by precisely engaging both IL18R1 and IL18RAP, can modulate these disease-associated pathways. The dual-targeting approach is strategically valuable for overcoming tumor heterogeneity and immune evasion—a key consideration in developing advanced immunotherapies for colorectal cancer.

Mechanism of Action

VHH-P312 operates by specifically binding to the extracellular domains of IL18R1 and IL18RAP, thereby blocking the assembly and activation of the IL-18 receptor complex. Through high-affinity, dual engagement of these targets, the nanobody inhibits downstream IL-18-mediated immune signaling, which is associated with promoting inflammation and altering the tumor microenvironment in colorectal cancer. This mechanism may lead to the suppression of pro-tumorigenic immune responses and attenuation of cytokine-driven tumor progression. Given its modular nanobody structure and bispecificity, VHH-P312 also exemplifies the technical flexibility of the platform, with potential applications in antibody–drug conjugates (ADC), multispecific modalities, and other tailored immunotherapeutics across oncology indications.

Colorectal Cancer

Colorectal cancer is one of the most prevalent malignancies worldwide and remains a leading cause of cancer-related mortality. Affected patients may present with localized, advanced, or metastatic disease. While surgery, chemotherapy, radiation, and targeted therapeutics represent the current mainstays of treatment, significant limitations persist, including resistance, adverse effects, and the absence of curative options for advanced or refractory cases. Immunotherapies have provided new hope but are effective in only a subset of patients, highlighting a need for innovative therapeutic agents capable of overcoming microenvironment-mediated immune suppression and tumor heterogeneity. By precisely targeting IL18R1 and IL18RAP, VHH-P312 offers a novel avenue for modulating key immunological pathways implicated in colorectal cancer pathophysiology, potentially expanding treatment options and improving patient outcomes in this high-burden disease area.